Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Springworks Therapeutics ( (SWTX) ) is now available.
On April 27, 2025, SpringWorks Therapeutics entered into a Merger Agreement with Merck KGaA, Darmstadt, Germany, and EMD Holdings Merger Sub, Inc., which will result in SpringWorks becoming a wholly owned subsidiary of Merck KGaA. The merger has received necessary approvals from the Bundeskartellamt and the expiration of the waiting period under the HSR Act, with the finalization expected in the second half of 2025, pending satisfaction of remaining conditions including stockholder approval.
The most recent analyst rating on (SWTX) stock is a Hold with a $47.00 price target. To see the full list of analyst forecasts on Springworks Therapeutics stock, see the SWTX Stock Forecast page.
Spark’s Take on SWTX Stock
According to Spark, TipRanks’ AI Analyst, SWTX is a Neutral.
Springworks Therapeutics holds potential due to its strong revenue growth and the strategic merger with Merck. However, ongoing profitability and cash flow challenges, coupled with a negative P/E ratio, weigh on the stock’s attractiveness. Technical indicators show upward momentum, but caution is advised due to potential overbought conditions.
To see Spark’s full report on SWTX stock, click here.
More about Springworks Therapeutics
SpringWorks Therapeutics, Inc. is a Delaware-based company operating in the biopharmaceutical industry, focusing on the development of medicines for patients with severe rare diseases and cancer.
Average Trading Volume: 5,151,250
Technical Sentiment Signal: Buy
Current Market Cap: $3.52B
Find detailed analytics on SWTX stock on TipRanks’ Stock Analysis page.